Dynavax Technologies Corp (DVAX) Stock AnalysisDVAXStock AnalysisDynavax Technologies Corp

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

- Not a good buy right now: the stock is trading essentially exactly at the announced acquisition price ($15.50), which caps upside while leaving downside if the deal is delayed/changed/breaks. - Sentiment is net negative (hedge funds and insiders selling), which is typical into a takeout but still weak for a fresh entry. - With no Intellectia buy signal and limited merger-arb spread, the risk/reward is unfavorable for an impatient buyer looking for near-term upside.

6 analysts cover DVAX: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 20.50.